Novartis to Co-Develop Cancer Drug With China's BeiGene
February 26 2021 - 6:48AM
Dow Jones News
By Cecilia Butini
Novartis AG said Friday that it will co-develop cancer drug
tislelizumab with China-based pharmaceutical company BeiGene as
part of an in-licensing agreement.
The Swiss pharma giant said it will initiate additional clinical
trials to study the drug's efficacy on different types of cancer,
as tislelizumab is now only approved in China for patients with
non-small cell lung cancer, classical Hodgkin's lymphoma and
metastatic urothelial carcinoma.
The agreement--the financial details of which weren't
disclosed--is valid for North America, Europe and Japan, Novartis
said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
February 26, 2021 07:33 ET (12:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2024 to May 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From May 2023 to May 2024